FindTrial
Sign In

Study of Infliximab Therapy for Multiple Treatment(included IVIG)-resistant Kawasaki Disease

Study of Infliximab Therapy for Multiple Treatment(included IVIG)-resistant Kawasaki Disease

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT1091220201
Enrollment
20
Registered
2014-12-09
Start date
2014-12-02
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kawasaki Disease

Interventions

Intervention type:DRUG Name of intervention:Study of Infliximab Therapy for Multiple Treatment (included IVIG)-resistant Kawasaki Disease Dose form / Japanese Medical Device Nomenclature:INJECTION Rou

Sponsors

Investigator-initiated Clinical Research(in-house)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients against Multiple Treatment(included IVIG)-resistant Kawasaki Disease (Under 37.5 degrees C within a 48-hour period)

Exclusion criteria

Exclusion criteria: Past History of Demyelinating Disease Patients less than 6 months of taking BCG Patients with lung tuberculosis

Design outcomes

Primary

MeasureTime frame
Less than 37.5 degrees C within a 48-hour period after injection—

Secondary

MeasureTime frame
Complication of Coronary Artery Aneurysm after Injection Complication of Coronary Artery Aneurysm after Injection(Up to One year after Injection) Change of inflamatory biomarker Adverse Event—

Countries

Japan

Contacts

Public ContactHiroshi Ono

National Center for Child Health and Development

+81-3-3416-0181

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026